Funding will not be a problem for us anymore. It’s just the level of dilution that we may need to leave with. We are stronger now than we have ever been.
We also need to remember that the primary end point of the FDA EFS is only 30 days and we could have that by years end or at least Q1 2023. Plus the 12 month data for the first cohort is being presented at London Valves in late November.
Not to mention that we could get Breakthrough Device Designation any day now.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add to My Watchlist
What is My Watchlist?
